Matrx’s drug-delivery technology and new drug development focus on several important areas of ophthalmology including glaucoma, macular degeneration, and diabetic-induced retinopathy.
Matrx’s SĀPH™ drug delivery technology provides for the controlled, sustained release of approved, generic medicines for the treatment of glaucoma (β-blockers, carbonic anhydrase inhibitors, cholinergic receptor agonists) and macular degeneration (bevacizumab), or as the basis for new drug development targeted at diabetic retinopathy (PepClear-DR™).
Due to their bioadhesive and self-assembling qualities, ophthalmic medicines delivered using Matrx’s SĀPH™ platform are not easily removed through the naso-lacrimal drainage providing controlled release over extended periods. Combined with the superior ocular clarity offered by Matrx’s SĀPH™ technology, patients can experience extended delivery options without compromising vision.